All Posts By

Smartkarma Daily Briefs

Daily Brief Industrials: Daiseki Co Ltd, Qantm Intellectual Property and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Daiseki Co Ltd (9793 JP): Q1 FY02/25 flash update
  • Qantm Intellectual Property – “Fair and reasonable”: says independent expert


Daiseki Co Ltd (9793 JP): Q1 FY02/25 flash update

By Shared Research

  • In Q1 FY02/25, Daiseki reported sales of JPY16.7bn (-6.6% YoY), gross profit of JPY5.9bn (-1.1% YoY), and operating profit of JPY3.9bn (-0.7% YoY).
  • Daiseki Co.’s sales increased 7.0% YoY, while DES’s sales fell 28.4% YoY, leading to a consolidated sales decrease.
  • Consolidated operating profit for Q1 decreased by 0.7% YoY to JPY3.9bn, with OPM rising 1.4pp to 23.4%.

Qantm Intellectual Property – “Fair and reasonable”: says independent expert

By Research as a Service (RaaS)

  • RaaS Reseach Group has published an update report on IP services group QANTM Intellectual Property (ASX:QIP) following the release of the Scheme of Arrangement documentation with Adamantem Capital on 25 June.The documentation includes the Independent Expert’s report from Grant Thornton Corporate Finance which concludes that the Scheme is “fair and reasonable” and in the “best interests of QANTM shareholders in the absence of a superior alternative proposal emerging”.
  • The independent expert concludes that the fair market value range for QANTM shares on a control basis is from $1.736/share to $2.098/share, suggesting a respective premium of 4.7% and discount of 13.4% to the cash offer of $1.817/share.
  • Our existing DCF-based valuation has remained unchanged at $1.79/share.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: China Traditional Chinese Medicine, Celltrion Inc, ABLBio, Samsung Biologics , Fresenius Medical Care & , Elanco Animal Health , Ionis Pharmaceuticals, Globus Medical Inc A, Dentsply International and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • China TCM (570.HK) Update – Behind The Share Price Plunge and Prospects for Privatization Progress
  • Alpha Generation Through Share Buybacks in Korea: Bi-Monthly (May and June 2024)
  • ABL Bio Capital Raise of 140 Billion Won
  • Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares
  • Fresenius Medical Care AG & Co.: How Are They Executing Portfolio Optimization through Divestitures? – Major Growth Drivers
  • Elanco Animal Health Incorporated: Will The Accelerated Global Rollout of Zenrelia Boost Its Top-Line? – Major Growth Drivers
  • Ionis Pharmaceuticals Inc.: Expanding Pipeline with Promising Drug Candidates! – Major Growth Drivers
  • Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? – Major Growth Drivers
  • DENTSPLY SIRONA Inc.: Facing Economic Headwinds with a Strategic Focus on Orthodontics and Imaging! – Major Growth Drivers


China TCM (570.HK) Update – Behind The Share Price Plunge and Prospects for Privatization Progress

By Xinyao (Criss) Wang

  • The slow progress of privatization is related to recent high-level changes in CNPGC. Decisions on SOE deals with “strategic purpose” require careful considerations, not based on “one leader’s personal preferences”.
  • Based on public information, we cannot find convincing reason to prove that CNPGC has changed its mind.There’re rumors that China TCM’s privatization is still considered important project on the agenda.
  • China TCM’s has strong fundamentals to support valuation. If there is no announcement, the privatization process is expected to proceed as usual, and we continue to wait for the voting.  

Alpha Generation Through Share Buybacks in Korea: Bi-Monthly (May and June 2024)

By Douglas Kim

  • In this insight, we discuss the alpha generation through companies that have been buying back their shares in the Korean stock market in May and June 2024.
  • On average, the share buyback announcements for the 13 companies that announced share buybacks in Korea represented 1.7% of outstanding shares.
  • Major companies that have announced share buybacks in Korea in the past two months include Celltrion Inc (068270 KS), SK IE Technology (361610 KS), and NCSOFT Corp (036570 KS).

ABL Bio Capital Raise of 140 Billion Won

By Douglas Kim

  • On 2 July, ABL Bio (298380 KS) announced a capital raise worth 140 billion won. 
  • The capital raise involves 5.77 million new shares (10.7% of outstanding shares post capital raise) at 24,229 won per share (current price is 24,150 won).
  • The proceeds from the capital raise will be used to develop next-generation ADCs (Antibody Drug Conjugates), including bispecific antibody ADCs.

Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares

By Tina Banerjee

  • Samsung Biologics (207940 KS) has signed the largest ever single CMO contract worth KRW1.46T ($1.1B) with an undisclosed U.S.-based pharmaceutical company. The contract value represents ~40% of 2023 standalone revenue.
  • Within the first half of the year, Samsung Biologics has secured order worth of KRW2.6T, compared with order win of KRW3.5T in full-year 2023.
  • Samsung Bioepis has received FDA approval for Stelara biosimilar Pyzchiva, which is expected to marketed in early 2025. So far, the FDA has approved two other biosimilars of Stelara.  

Fresenius Medical Care AG & Co.: How Are They Executing Portfolio Optimization through Divestitures? – Major Growth Drivers

By Baptista Research

  • Fresenius Medical Care, in its recent financial results, highlighted its commitment to continuing transformation and improvement across its segments.
  • Initiatives to streamline organizational structures, enhance clinic utilization, and advance strategic growth areas, notably in value-based care, were emphasized.
  • The company’s focus on optimizing manufacturing and supply chain processes is a critical element in its strategy to achieve margin improvements by 2025.

Elanco Animal Health Incorporated: Will The Accelerated Global Rollout of Zenrelia Boost Its Top-Line? – Major Growth Drivers

By Baptista Research

  • Elanco Animal Health Incorporated has demonstrated a strong start to 2024 with positive developments in multiple areas of its business, despite facing some challenges.
  • The company has achieved encouraging financial and operational results, underscored by success in its strategic initiatives aimed at enhancement and innovation.
  • Starting with the financials, Elanco surpassed its revenue, adjusted EBITDA, and adjusted EPS guidance for Q1 2024, indicating robust underlying business performance.

Ionis Pharmaceuticals Inc.: Expanding Pipeline with Promising Drug Candidates! – Major Growth Drivers

By Baptista Research

  • Ionis Pharmaceuticals commenced the year 2024 with notable strides, particularly through the launch of WAINUA in the U.S. This product, among others in the pipeline, is expected to lead the company towards a more independent operation in drug commercialization.
  • The company’s executives displayed confidence in the potential of upcoming products like olezarsen and donidalorsen to transform their respective therapeutic areas and achieve market penetration based on strong clinical results.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? – Major Growth Drivers

By Baptista Research

  • Globus Medical recently disclosed its financial results for the first quarter of 2024, showcasing significant growth and strategic advancements post the integration with NuVasive.
  • The company reported a remarkable 119% increase in sales, reaching $607 million, and a 36% rise in non-GAAP EPS to $0.72.
  • This period marks the first quarter of the combined field organizations of Globus and NuVasive, underscoring a robust integration process aimed at streamlining operations and escalating market reach.

DENTSPLY SIRONA Inc.: Facing Economic Headwinds with a Strategic Focus on Orthodontics and Imaging! – Major Growth Drivers

By Baptista Research

  • DENTSPLY SIRONA reported its results for the first quarter of 2024, shedding light on both the advancements and ongoing challenges within its diverse portfolio.
  • The company’s organic sales saw a slight decrease, declining by 1.9%, affected largely by lower sales in its Connected Technology Solutions (CTS) and Essential Dental Solutions (EDS) segments, although this was partially offset by growth in Orthodontic & Implant Solutions and Wellspect HealthCare.
  • CTS notably faced headwinds due to unfavorable macroeconomic conditions and competitive pressures, particularly in imaging equipment.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: MS&AD Insurance, HDFC Bank, Deutsche Beteiligungs AG, Jackson Financial and more

By | Daily Briefs, Financials

In today’s briefing:

  • Japan CorpGovReport Details: TSE “Mgmt Conscious of Capital Cost/Stock Price” Details (Jul24)
  • HDFC Bank (HDFCB IN): Foreign Room Crosses 25%; Index Implications & Positioning for US$5bn+ Buying
  • Deutsche Beteiligungs – Convertible bond issue
  • Jackson Financial Inc (JXN) – Tuesday, Apr 2, 2024


Japan CorpGovReport Details: TSE “Mgmt Conscious of Capital Cost/Stock Price” Details (Jul24)

By Travis Lundy

  • This month (June) saw 1,673 Corporate Governance Reports filed and 5 new “Mgmt Conscious of Capital Cost/Stock Price” policies filed. 
  • We created a tool show every report, provide links to every document, and now a new diff file tool. Put in a name, see the difference between the Old/New Reports.
  • We hope this took will help. It is designed to be a shelf reference. We update the tool once a month, a couple of weeks ahead of the TSE.

HDFC Bank (HDFCB IN): Foreign Room Crosses 25%; Index Implications & Positioning for US$5bn+ Buying

By Brian Freitas

  • Foreign shareholding in HDFC Bank (HDFCB IN) has dropped to 54.83% and that results in foreign room crossing the ‘magical’ 25% mark.
  • The increase in foreign room could lead to passive trackers of a global index needing to buy 256m shares (US$5.3bn; 11.5x ADV) at the end of August.
  • There will definitely be positioning in the stock but there should still be upside in the stock. The HDFC Bank (ADR) (HDB US) line was up 4.5% overnight.

Deutsche Beteiligungs – Convertible bond issue

By Edison Investment Research

Deutsche Beteiligungs (DBAG) completed an issue of €100m senior unsecured convertible bonds on 28 July, with proceeds to be used for co-investments alongside DBAG and ELF Capital funds, and for general corporate purposes. The bonds will bear interest at a fixed rate of 5.5% pa and mature in 2030. They are convertible into up to c 3.25m of new and/or existing DBAG shares, which is the equivalent of 17.3% of the currently outstanding number of shares.


Jackson Financial Inc (JXN) – Tuesday, Apr 2, 2024

By Value Investors Club

  • Jackson Financial is the 9th largest retail annuity company in the US with $12.8 billion in annuity sales in 2023
  • Spun from Prudential in 2021, JXN currently trades at 4x P/E and around 50% of book value
  • Plans to return $550-$650 million of capital to shareholders this year, representing 11-13% of its market cap, through dividends and share repurchases, with potential for growth in the future

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Honda Motor, Stella International, Fast Retailing, Tripadvisor Inc, TSE Tokyo Price Index TOPIX, Casino Guichard Perrachon Sa, Guess? Inc, Freshpet Inc, Lancaster Colony, Pointerra Ltd and more

By | Consumer, Daily Briefs

In today’s briefing:

  • BIG ¥500bn Honda (7267) Offering Coming?
  • HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September
  • Fast Retailing (9983) | Red Hot Summer
  • TripAdvisor Inc.: Focus on User Engagement and Monetization Strategies & Other Major Growth Drivers
  • Key to Look Carefully to See if What Is Disclosed Is Consistent with Profitability and Other Results
  • Casino Guichard-Perrachon – ESG Report – Lucror Analytics
  • GES: Snapping the Store – London Edition – All in on Elevation – Reiterate Buy
  • Freshpet Inc.: Will Its Strategic Investments in Consumer Reach and Product Availability Pay Off? – Major Growth Drivers
  • Lancaster Colony Corporation: Will Its Focus on Cost-Efficiency Programs Improve The Bottom-Line?
  • Pointerra Ltd – Good start to FY25 with US Dept of Energy contract


BIG ¥500bn Honda (7267) Offering Coming?

By Travis Lundy

  • Today just before the close, Reuters came out with an article saying Japan’s four major insurers and some financial institutions would offer ¥500bn of shares in a secondary offering.
  • That implies about 275-280mm shares (insurers hold ~195mm). In May, Honda announced a ¥300bn buyback with earnings, with nothing done so far. 
  • The supply/demand dynamics here are key. There are a lot of moving parts over time. Honda is cheaper than it looks but there are moving parts there too.

HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September

By Brian Freitas

  • We see 37 potential adds (including plenty of new listings) and 25 potential deletes (on market cap and liquidity) for the Hang Seng Composite Index in September.
  • We expect 32 stocks to be added to Southbound Stock Connect following the rebalance while 24 stocks could be deleted from the trading link and become Sell-only.
  • There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.

Fast Retailing (9983) | Red Hot Summer

By Mark Chadwick

  • Domestic Uniqlo SSS (including e-commerce) were +14.9% in June. Positive
  • Impressive +8.1% increase in customer traffic and +6.3% gain in per-customer spend
  • I have a bearish view on Fast Retailing due to rich valuations (25x EV/EBIT). However, the share price may perform well in the run up to the Q3 report.

TripAdvisor Inc.: Focus on User Engagement and Monetization Strategies & Other Major Growth Drivers

By Baptista Research

  • Tripadvisor’s fourth quarter and full year 2023 financial results exceeded expectations with the company reporting revenue growth of 10% year-on-year amounting to $390 million in Q4.
  • In the same period, the adjusted EBITDA was $84 million attributed to exceptional brand performance and marketing efficiencies.
  • For the full year, the company reported a consolidated revenue growth of 20%, recording an all-time high of $1.8 billion, with adjusted EBITDA experiencing a 13% growth to $334 million.

Key to Look Carefully to See if What Is Disclosed Is Consistent with Profitability and Other Results

By Aki Matsumoto

  • The problem with cross-shareholdings is not simply that they weigh heavily on ROE and ROA improvement, but also that they do not create tension in management.
  • The degree of seriousness of the company’s efforts to reduce policy shareholdings is a measure of the improvement in return on capital. The level of seriousness must be monitored.
  • The fact that there are inappropriate entries in the items required of prime market listed companies indicates that many companies are not suitable for prime market listed companies.

Casino Guichard-Perrachon – ESG Report – Lucror Analytics

By Tanvi Arora

Lucror Analytics’ ESG Scores are based on a 3-tiered scale and are adjusted for Controversies (if applicable).
We assess Casino Guichard-Perrachon’s ESG as “Adequate”, in line with its Environmental score, while the Social pillar is “Strong”. We assess Governance as “Weak” due to a lack of data following the company’s recent debt restructuring, which led to a change of control. Controversies are “Material”, while Disclosure is “Strong”. 


GES: Snapping the Store – London Edition – All in on Elevation – Reiterate Buy

By Small Cap Consumer Research

  • We are reiterating our Buy rating, $37 price target and projections for Guess?
  • after visiting stores in London.
  • We believe the company has continued to raise their fashion game worldwide, increasing overall elevation levels and remaining focused on creating a global fashion powerhouse.

Freshpet Inc.: Will Its Strategic Investments in Consumer Reach and Product Availability Pay Off? – Major Growth Drivers

By Baptista Research

  • Investment analysis and result summary for Freshpet’s first quarter of 2024 show a mixed yet optimistic outlook for the company’s financial and operational progress.
  • The company reported a robust 34% increase in net sales amounting to $223.8 million, mainly driven by substantial volume growth of 31%.
  • This positive development suggests a successful adaptation to significant pricing changes, highlighting effective management and resilient operational frameworks.

Lancaster Colony Corporation: Will Its Focus on Cost-Efficiency Programs Improve The Bottom-Line?

By Baptista Research

  • Lancaster Colony Corporation recently reported its fiscal year 2024 third quarter results, highlighting a mixed performance with significant strategic adjustments.
  • The company achieved record net sales and gross profit, with consolidated net sales increasing by 1.4% to $471.4 million and gross profit growing by 10.9% to $104.5 million.
  • Notably, operating income saw a substantial rise of 19.5% to $35.1 million, reflecting robust underlying business performance despite some challenges.

Pointerra Ltd – Good start to FY25 with US Dept of Energy contract

By Research as a Service (RaaS)

  • RaaS Research Group has published an update on cloud-based digital twin solution provider Pointerra (ASX:3DP) following the announcement it has been awarded a US$1.63m contract for a US Department of Energy programme to model a range of electric grid resilience investment scenarios by electric utilities.
  • We see the contract as validation of Pointerra’s digital twin solution for managing large-scale physical inventory with the potential to provide the company with invaluable exposure to new and existing US clients in the US electric utility sector.
  • We have not made any changes to our forecasts as a result of this announcement, although note that we have already factored in substantial revenue growth in FY25f.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Australia: Qantm Intellectual Property, Pointerra Ltd and more

By | Australia, Daily Briefs

In today’s briefing:

  • Qantm Intellectual Property – “Fair and reasonable”: says independent expert
  • Pointerra Ltd – Good start to FY25 with US Dept of Energy contract


Qantm Intellectual Property – “Fair and reasonable”: says independent expert

By Research as a Service (RaaS)

  • RaaS Reseach Group has published an update report on IP services group QANTM Intellectual Property (ASX:QIP) following the release of the Scheme of Arrangement documentation with Adamantem Capital on 25 June.The documentation includes the Independent Expert’s report from Grant Thornton Corporate Finance which concludes that the Scheme is “fair and reasonable” and in the “best interests of QANTM shareholders in the absence of a superior alternative proposal emerging”.
  • The independent expert concludes that the fair market value range for QANTM shares on a control basis is from $1.736/share to $2.098/share, suggesting a respective premium of 4.7% and discount of 13.4% to the cash offer of $1.817/share.
  • Our existing DCF-based valuation has remained unchanged at $1.79/share.

Pointerra Ltd – Good start to FY25 with US Dept of Energy contract

By Research as a Service (RaaS)

  • RaaS Research Group has published an update on cloud-based digital twin solution provider Pointerra (ASX:3DP) following the announcement it has been awarded a US$1.63m contract for a US Department of Energy programme to model a range of electric grid resilience investment scenarios by electric utilities.
  • We see the contract as validation of Pointerra’s digital twin solution for managing large-scale physical inventory with the potential to provide the company with invaluable exposure to new and existing US clients in the US electric utility sector.
  • We have not made any changes to our forecasts as a result of this announcement, although note that we have already factored in substantial revenue growth in FY25f.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief South Korea: Celltrion Inc, ABLBio, Samsung Biologics and more

By | Daily Briefs, South Korea

In today’s briefing:

  • Alpha Generation Through Share Buybacks in Korea: Bi-Monthly (May and June 2024)
  • ABL Bio Capital Raise of 140 Billion Won
  • Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares


Alpha Generation Through Share Buybacks in Korea: Bi-Monthly (May and June 2024)

By Douglas Kim

  • In this insight, we discuss the alpha generation through companies that have been buying back their shares in the Korean stock market in May and June 2024.
  • On average, the share buyback announcements for the 13 companies that announced share buybacks in Korea represented 1.7% of outstanding shares.
  • Major companies that have announced share buybacks in Korea in the past two months include Celltrion Inc (068270 KS), SK IE Technology (361610 KS), and NCSOFT Corp (036570 KS).

ABL Bio Capital Raise of 140 Billion Won

By Douglas Kim

  • On 2 July, ABL Bio (298380 KS) announced a capital raise worth 140 billion won. 
  • The capital raise involves 5.77 million new shares (10.7% of outstanding shares post capital raise) at 24,229 won per share (current price is 24,150 won).
  • The proceeds from the capital raise will be used to develop next-generation ADCs (Antibody Drug Conjugates), including bispecific antibody ADCs.

Samsung Biologics (207940 KS): Gaining Momentum on New Approval and Contract Wins; Hold Shares

By Tina Banerjee

  • Samsung Biologics (207940 KS) has signed the largest ever single CMO contract worth KRW1.46T ($1.1B) with an undisclosed U.S.-based pharmaceutical company. The contract value represents ~40% of 2023 standalone revenue.
  • Within the first half of the year, Samsung Biologics has secured order worth of KRW2.6T, compared with order win of KRW3.5T in full-year 2023.
  • Samsung Bioepis has received FDA approval for Stelara biosimilar Pyzchiva, which is expected to marketed in early 2025. So far, the FDA has approved two other biosimilars of Stelara.  

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Singapore: NetLink NBN Trust and more

By | Daily Briefs, Singapore

In today’s briefing:

  • 10 in 10 with NetLink NBN Trust – The Fibre of a Smart Nation


10 in 10 with NetLink NBN Trust – The Fibre of a Smart Nation

By Geoff Howie

10 in 10 with NetLink NBN Trust – The Fibre of a Smart Nation

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief United States: NVIDIA Corp, Amazon.com Inc, Tripadvisor Inc, Elanco Animal Health , Ionis Pharmaceuticals, Aptargroup Inc, Flowers Foods, Freshpet Inc, Globus Medical Inc A, Graphic Packaging Holding Company and more

By | Daily Briefs, United States

In today’s briefing:

  • NVIDIA’s Conundrum…
  • Remain Overweight Large-Cap Growth; Downgrading Materials to Underweight; Software Buys $MSTR $CRWD
  • TripAdvisor Inc.: Focus on User Engagement and Monetization Strategies & Other Major Growth Drivers
  • Elanco Animal Health Incorporated: Will The Accelerated Global Rollout of Zenrelia Boost Its Top-Line? – Major Growth Drivers
  • Ionis Pharmaceuticals Inc.: Expanding Pipeline with Promising Drug Candidates! – Major Growth Drivers
  • AptarGroup Inc.: A Tale Of Recovery and Growth in North American Markets! – Major Growth Drivers
  • Flowers Foods Inc.: How Are They Executing The Expansion in High-Margin Business Segments?
  • Freshpet Inc.: Will Its Strategic Investments in Consumer Reach and Product Availability Pay Off? – Major Growth Drivers
  • Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? – Major Growth Drivers
  • Graphic Packaging Holding Company: Is The Volume Growth & Market Expansion Here To Stay? – Major Growth Drivers


NVIDIA’s Conundrum…

By William Keating

  • NVIDIA’s data center revenues tripled YoY in CY 2023 and are on track to more than double in CY 2024
  • When Intel dominated the data centre and minted tens of billions annually, its customers benefited even more, minting hundreds of billions. 
  • If NVIDIA’s business model succeeds, its customers will succeed even more. This will make it extremely difficult for NVIDIA to remain the #1 global market cap stock. 

Remain Overweight Large-Cap Growth; Downgrading Materials to Underweight; Software Buys $MSTR $CRWD

By Joe Jasper

  • Mega-Cap growth names such as AMZN, TSLA, MSFT, GOOGL, and META have picked up the slack as semiconductors (SMH, SOXX, NVDA, AVGO, etc.) are simply consolidating after getting extended.
  • This was a possibility we discussed in last week’s Compass (6/25/24), which means we are not seeing any lasting rotation away from large-cap growth.
  • We remain bullish on all names listed (including the semiconductors), and we continue to recommend an overweight to large-cap growth (relative to value) as initially discussed in our 5/29/24 Compass

TripAdvisor Inc.: Focus on User Engagement and Monetization Strategies & Other Major Growth Drivers

By Baptista Research

  • Tripadvisor’s fourth quarter and full year 2023 financial results exceeded expectations with the company reporting revenue growth of 10% year-on-year amounting to $390 million in Q4.
  • In the same period, the adjusted EBITDA was $84 million attributed to exceptional brand performance and marketing efficiencies.
  • For the full year, the company reported a consolidated revenue growth of 20%, recording an all-time high of $1.8 billion, with adjusted EBITDA experiencing a 13% growth to $334 million.

Elanco Animal Health Incorporated: Will The Accelerated Global Rollout of Zenrelia Boost Its Top-Line? – Major Growth Drivers

By Baptista Research

  • Elanco Animal Health Incorporated has demonstrated a strong start to 2024 with positive developments in multiple areas of its business, despite facing some challenges.
  • The company has achieved encouraging financial and operational results, underscored by success in its strategic initiatives aimed at enhancement and innovation.
  • Starting with the financials, Elanco surpassed its revenue, adjusted EBITDA, and adjusted EPS guidance for Q1 2024, indicating robust underlying business performance.

Ionis Pharmaceuticals Inc.: Expanding Pipeline with Promising Drug Candidates! – Major Growth Drivers

By Baptista Research

  • Ionis Pharmaceuticals commenced the year 2024 with notable strides, particularly through the launch of WAINUA in the U.S. This product, among others in the pipeline, is expected to lead the company towards a more independent operation in drug commercialization.
  • The company’s executives displayed confidence in the potential of upcoming products like olezarsen and donidalorsen to transform their respective therapeutic areas and achieve market penetration based on strong clinical results.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

AptarGroup Inc.: A Tale Of Recovery and Growth in North American Markets! – Major Growth Drivers

By Baptista Research

  • Aptar, a global leader in drug delivery systems and consumer product dispensing, has reported robust first quarter financial results for 2024.
  • The company disclosed a 5% core sales growth and a remarkable more than 30% increase in adjusted earnings per share (EPS) as compared to the previous year.
  • Notably, the Pharma segment exhibited strong performance driven by sustained demand for its proprietary drug delivery systems, marking high single-digit core sales growth.

Flowers Foods Inc.: How Are They Executing The Expansion in High-Margin Business Segments?

By Baptista Research

  • Flowers Foods, a packaged bakery goods company, recently discussed their first quarter 2024 financial results, highlighting a mix of both successes and ongoing challenges.
  • They remained optimistic about the future, reinforcing their strategy based on portfolio optimization and cost efficiency.
  • In terms of performance, the company reported solid results with an improvement in branded retail volumes for the first time since 2020.

Freshpet Inc.: Will Its Strategic Investments in Consumer Reach and Product Availability Pay Off? – Major Growth Drivers

By Baptista Research

  • Investment analysis and result summary for Freshpet’s first quarter of 2024 show a mixed yet optimistic outlook for the company’s financial and operational progress.
  • The company reported a robust 34% increase in net sales amounting to $223.8 million, mainly driven by substantial volume growth of 31%.
  • This positive development suggests a successful adaptation to significant pricing changes, highlighting effective management and resilient operational frameworks.

Globus Medical Inc.: How Are Their Strategic Acquisitions and Partnerships Catalyzing Growth? – Major Growth Drivers

By Baptista Research

  • Globus Medical recently disclosed its financial results for the first quarter of 2024, showcasing significant growth and strategic advancements post the integration with NuVasive.
  • The company reported a remarkable 119% increase in sales, reaching $607 million, and a 36% rise in non-GAAP EPS to $0.72.
  • This period marks the first quarter of the combined field organizations of Globus and NuVasive, underscoring a robust integration process aimed at streamlining operations and escalating market reach.

Graphic Packaging Holding Company: Is The Volume Growth & Market Expansion Here To Stay? – Major Growth Drivers

By Baptista Research

  • Graphic Packaging Holding Company’s performance in the first quarter of 2024 presents a mixed picture.
  • Despite challenging market conditions, the company demonstrated resilience, attributed to its diversified portfolio and strategic initiatives, which may hold implications for stakeholders considering investment in the firm.
  • On the revenue front, Graphic Packaging saw its sales reach $2.3 billion.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief India: HDFC Bank, Ratnaveer Precision Engineering and more

By | Daily Briefs, India

In today’s briefing:

  • HDFC Bank (HDFCB IN): Foreign Room Crosses 25%; Index Implications & Positioning for US$5bn+ Buying
  • The Beat Ideas- Ratnaveer Precision Engineering: Fueled with Capacity Expansion


HDFC Bank (HDFCB IN): Foreign Room Crosses 25%; Index Implications & Positioning for US$5bn+ Buying

By Brian Freitas

  • Foreign shareholding in HDFC Bank (HDFCB IN) has dropped to 54.83% and that results in foreign room crossing the ‘magical’ 25% mark.
  • The increase in foreign room could lead to passive trackers of a global index needing to buy 256m shares (US$5.3bn; 11.5x ADV) at the end of August.
  • There will definitely be positioning in the stock but there should still be upside in the stock. The HDFC Bank (ADR) (HDB US) line was up 4.5% overnight.

The Beat Ideas- Ratnaveer Precision Engineering: Fueled with Capacity Expansion

By Sudarshan Bhandari

  • 23,000 MT Capacity expansion would double the current capacity to 49,000 MT  
  • INR 65 crores of Fund Raise would help increase the bottom line
  • Backward integration of waste converted into raw material, ensuring economies of scale

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: China Traditional Chinese Medicine, Stella International, ASM Pacific Technology, Chenqi Technology Limited and more

By | China, Daily Briefs

In today’s briefing:

  • China TCM (570.HK) Update – Behind The Share Price Plunge and Prospects for Privatization Progress
  • HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September
  • HSTECH Index Rebalance Preview: ASM Pacific (522) Could Replace Ping An Health (1833); US$1bn Trade
  • Chenqi Technology IPO – Smallest in Scale, Sentiment Might Not Be the Best


China TCM (570.HK) Update – Behind The Share Price Plunge and Prospects for Privatization Progress

By Xinyao (Criss) Wang

  • The slow progress of privatization is related to recent high-level changes in CNPGC. Decisions on SOE deals with “strategic purpose” require careful considerations, not based on “one leader’s personal preferences”.
  • Based on public information, we cannot find convincing reason to prove that CNPGC has changed its mind.There’re rumors that China TCM’s privatization is still considered important project on the agenda.
  • China TCM’s has strong fundamentals to support valuation. If there is no announcement, the privatization process is expected to proceed as usual, and we continue to wait for the voting.  

HSCI Index Rebalance Preview and Stock Connect: Potential Changes in September

By Brian Freitas

  • We see 37 potential adds (including plenty of new listings) and 25 potential deletes (on market cap and liquidity) for the Hang Seng Composite Index in September.
  • We expect 32 stocks to be added to Southbound Stock Connect following the rebalance while 24 stocks could be deleted from the trading link and become Sell-only.
  • There are stocks that have a very high percentage of holdings via Stock Connect and there could be some unwinding prior to the stocks becoming Sell-only.

HSTECH Index Rebalance Preview: ASM Pacific (522) Could Replace Ping An Health (1833); US$1bn Trade

By Brian Freitas


Chenqi Technology IPO – Smallest in Scale, Sentiment Might Not Be the Best

By Ethan Aw

  • Chenqi Technology Limited (CT HK) is looking to raise up to US$174m in its Hong Kong IPO, after downsizing from an earlier reported float of US$300m.
  • Chenqi Technology (Chenqi) is a mobility technology and service company in China, founded by the GAC Group and Tencent.
  • In our previous notes, we talked about the company’s historical performance and PHIP updates. In this note, we undertake a quick peer comparison and share our thoughts on valuation.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars